Biosimilars Forum Launches Education Initiative

February 8, 2016

On February 1, 2016, the Biosimilars Forum, a nonprofit organization dedicated to increasing biosimilar access in the US, announced the launch of “Partnership for Biosimilar Education and Access,” a new education initiative focused on raising awareness and encouraging access to biosimilars in the US.

In support of the initiative, the Forum has already “released two educational guides designed for health care professionals, media, and patient advocacy organizations to learn more about biosimilars”. Furthermore, using its “vast expertise on the science, development, manufacturing, regulation, and clinical applications of biological medicines and biosimilars,” the education tools provided by the Forum’s initiative are said to offer detailed background, insights, FAQs, and resources on biosimilars.

Juliana Reed, the Biosimilar Forum’s president, stated in a press release that the best treatments for some of the most difficult diseases in the US are biological medicines; and, she claims that “the introduction of biosimilars is anticipated to help drive lower cost burdens for the U.S. health care system. It will also help expand earlier, more consistent access to these important medicines for patients with cancer, anemia, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, psoriasis, and Crohn's and other inflammatory bowel diseases.”

The information associated with the Forum’s Partnership for Biosimilar Education and Access initiative is free and can be found on the Biosimilar Forum website.

Do you have a biosimilar product in development? Are you in the process of developing a BLA submission for your biosimilar product? We can help. To learn more about our services and our proprietary approach to FDA, contact us today.

Agency Alerts General Regulatory

October 5, 2015

Sandoz vs. Amgen, Round Two

Sandoz, the generic pharmaceuticals division of Novartis, is the global leader in biosimilar products. On March 6, 2015, FDA approved Zarxio, a biosimilar version of Amgen’s Neupogen (filgrastim)...

Read the Full Article
Agency Alerts General Regulatory

March 30, 2016

FDA Amends IND & Bioequivalence Regulations

On Monday, March 28th the FDA announced that it is amending its current IND and bioequivalence regulations. Specifically, FDA stated that it is changing “its regulations to update the address for...

Read the Full Article
Agency Alerts General Regulatory

May 4, 2017

CREATES Act Reintroduced in House & Senate

On Thursday, April 27th, the “Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act was reintroduced by members of the Senate & House Judiciary Committees.  The CREATES Act is a...

Read the Full Article